Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of colorectal cancer called MSS (microsatellite stable) or pMMR (proficient mismatch repair).
- You have cancer that has spread to your liver, but a surgeon can remove all of the liver spots.
- You are in good enough health to have surgery (ECOG performance status 0 or 1).
- You are at least 18 years old.
- Your blood counts, kidney function, and liver function are within safe ranges (your doctor will check these).
- You are not pregnant, not nursing, and willing to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.